Associated Papers
Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response.
Hong JY et al.
Cancer Research and Treatment, 2023
36164943 (PubMed )
Supplement: crt-2022-251-Supplementary-Table-2.xlsx › S3_Table
Molecular and clinical features of papillary thyroid cancer in adult patients with a non-classical phenotype.
Zhou J et al.
Frontiers in Endocrinology, 2023
37124750 (PubMed )
Supplement: Table_6.xlsx › Sheet1
Integrated driver mutations profile of chinese gastrointestinal-natural killer/T-cell lymphoma.
Li S et al.
Frontiers in Oncology, 2022
RETSAT Mutation Selected for Hypoxia Adaptation Inhibits Tumor Growth.
Jiang X et al.
Frontiers in Cell and Developmental Biology, 2021
Molecular Characterization of Astrocytoma Progression Towards Secondary Glioblastomas Utilizing Patient-Matched Tumor Pairs.
Seifert M et al.
Cancers, 2020
32604718 (PubMed )
Supplement: cancers-12-01696-s001.zip › Supporting_Tables_and_Figures › Table_S8_ExomeSeq_Predictions.xlsx › MuTect_SNV_Predictions
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.
Diplas BH et al.
Nature Communications, 2018
29802247 (PubMed )
Supplement: 41467_2018_4448_MOESM11_ESM.xlsx › 8_SNV_WGS
Case Report: Exome sequencing reveals recurrent RETSAT mutations and a loss-of-function POLDIP2 mutation in a rare undifferentiated tongue sarcoma.
Chan JYK et al.
F1000research, 2018
Mutational heterogeneity in non-serous ovarian cancers.
Teer JK et al.
Scientific Reports, 2017
28852190 (PubMed )
Supplement: 41598_2017_10432_MOESM2_ESM.xlsx › Supp_Table_11
Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations.
Kim YH et al.
Oncotarget, 2016
27009864 (PubMed )
Supplement: oncotarget-07-23825-s001.pdf
Select a paper to view details